Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973020 | PMC |
| http://dx.doi.org/10.3779/j.issn.1009-3419.2018.02.09 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path institute, Tucson, AZ, USA.
Background: To help improve the Alzheimer's disease (AD) therapeutics research and development process, the Critical Path for Alzheimer's Disease (CPAD) Consortium at the Critical Path Institute (C-Path) provides a neutral framework for the drug development industry, regulatory agencies, academia, and patient advocacy organizations to collaborate. CPAD's extensive track record of developing regulatory-grade quantitative drug development tools motivates sponsors to share patient-level data and neuroimages from clinical trials. CPAD leverages these data and uses C-Path's core competencies in data management and standardization, quantitative modeling, and regulatory science to develop tools that help de-risk decision making in AD drug development.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Faculty of Medicine, University of Oslo, Oslo, Norway.
Background: While symptomatic treatment for Alzheimer's disease has been available for three decades disease modifying treatment does not exist. New drug treatments, known as immunotherapies, which remove amyloid from the brain offer hope, but the clinical significance remains uncertain.
Method: Systematic reviews of the literature, expert consensus, and information from clinical environments.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Senior Doc, Orange, CA, USA.
Background: Measuring the effectiveness of dementia care programs is essential for ensuring quality care and aligning with value-based care principles, especially in practical, real-world clinical settings. A Delphi method, a consensus-building approach among experts, was used to identify practical metrics for evaluating dementia programs. The expert panel comprised a clinical psychologist, two healthcare executives, and a physician experienced in person-centered care for older adults in residential and facility settings.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
The presentation of neuropsychiatric and sleep features in Lewy body dementia (LBD) are challenging to identify and manage. The US Based Diamond Lewy Neuropsychiatric Symptoms management guidelines provide expert consensus recommendations for the assessment and treatment of the neuropsychiatric features of LBD. These guidelines address the management of delusions, hallucinations, agitation and aggression, apathy, depression and anxiety.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!